Global Recombinant Human Granulocyte Colony-Stimulating Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Recombinant Human Granulocyte Colony-Stimulating market size was valued at US$ million in 2023. With growing demand in downstream market, the Recombinant Human Granulocyte Colony-Stimulating is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Recombinant Human Granulocyte Colony-Stimulating market. Recombinant Human Granulocyte Colony-Stimulating are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Recombinant Human Granulocyte Colony-Stimulating. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Recombinant Human Granulocyte Colony-Stimulating market.
Granulocyte-colony stimulating factor (G-CSF or GCSF), also known as colony-stimulating factor 3 (CSF 3), is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
Functionally, it is a cytokine and hormone, a type of colony-stimulating factor, and is produced by a number of different tissues. The pharmaceutical analogs of naturally occurring G-CSF are called filgrastim and lenograstim.
G-CSF also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils.
Key Features:
The report on Recombinant Human Granulocyte Colony-Stimulating market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Recombinant Human Granulocyte Colony-Stimulating market. It may include historical data, market segmentation by Type (e.g., Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Recombinant Human Granulocyte Colony-Stimulating market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Recombinant Human Granulocyte Colony-Stimulating market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Recombinant Human Granulocyte Colony-Stimulating industry. This include advancements in Recombinant Human Granulocyte Colony-Stimulating technology, Recombinant Human Granulocyte Colony-Stimulating new entrants, Recombinant Human Granulocyte Colony-Stimulating new investment, and other innovations that are shaping the future of Recombinant Human Granulocyte Colony-Stimulating.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Recombinant Human Granulocyte Colony-Stimulating market. It includes factors influencing customer ' purchasing decisions, preferences for Recombinant Human Granulocyte Colony-Stimulating product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Recombinant Human Granulocyte Colony-Stimulating market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Recombinant Human Granulocyte Colony-Stimulating market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Recombinant Human Granulocyte Colony-Stimulating market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Recombinant Human Granulocyte Colony-Stimulating industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Recombinant Human Granulocyte Colony-Stimulating market.
Market Segmentation:
Recombinant Human Granulocyte Colony-Stimulating market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global Recombinant Human Granulocyte Colony-Stimulating market?
What factors are driving Recombinant Human Granulocyte Colony-Stimulating market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Human Granulocyte Colony-Stimulating market opportunities vary by end market size?
How does Recombinant Human Granulocyte Colony-Stimulating break out type, application?
According to our LPI (LP Information) latest study, the global Recombinant Human Granulocyte Colony-Stimulating market size was valued at US$ million in 2023. With growing demand in downstream market, the Recombinant Human Granulocyte Colony-Stimulating is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Recombinant Human Granulocyte Colony-Stimulating market. Recombinant Human Granulocyte Colony-Stimulating are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Recombinant Human Granulocyte Colony-Stimulating. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Recombinant Human Granulocyte Colony-Stimulating market.
Granulocyte-colony stimulating factor (G-CSF or GCSF), also known as colony-stimulating factor 3 (CSF 3), is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
Functionally, it is a cytokine and hormone, a type of colony-stimulating factor, and is produced by a number of different tissues. The pharmaceutical analogs of naturally occurring G-CSF are called filgrastim and lenograstim.
G-CSF also stimulates the survival, proliferation, differentiation, and function of neutrophil precursors and mature neutrophils.
Key Features:
The report on Recombinant Human Granulocyte Colony-Stimulating market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Recombinant Human Granulocyte Colony-Stimulating market. It may include historical data, market segmentation by Type (e.g., Lenograstim (Granocyte), Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Recombinant Human Granulocyte Colony-Stimulating market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Recombinant Human Granulocyte Colony-Stimulating market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Recombinant Human Granulocyte Colony-Stimulating industry. This include advancements in Recombinant Human Granulocyte Colony-Stimulating technology, Recombinant Human Granulocyte Colony-Stimulating new entrants, Recombinant Human Granulocyte Colony-Stimulating new investment, and other innovations that are shaping the future of Recombinant Human Granulocyte Colony-Stimulating.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Recombinant Human Granulocyte Colony-Stimulating market. It includes factors influencing customer ' purchasing decisions, preferences for Recombinant Human Granulocyte Colony-Stimulating product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Recombinant Human Granulocyte Colony-Stimulating market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Recombinant Human Granulocyte Colony-Stimulating market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Recombinant Human Granulocyte Colony-Stimulating market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Recombinant Human Granulocyte Colony-Stimulating industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Recombinant Human Granulocyte Colony-Stimulating market.
Market Segmentation:
Recombinant Human Granulocyte Colony-Stimulating market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- Lenograstim (Granocyte)
- Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
- Others
- Chemotherapy Induced Neutropenia
- Before Blood Donation
- Stem Cell Transplants
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Amgen
- Qilu Pharmaceutical
- Shijiazhuang Pharmaceutical
- Kyowa Hakko Kirin
- Gensci
- Amoytop Biotech
- Hangzhou Jiuyuan
- Huaxin
- Triprime
- Sinovac
- Zhaoke
- Kawin
What is the 10-year outlook for the global Recombinant Human Granulocyte Colony-Stimulating market?
What factors are driving Recombinant Human Granulocyte Colony-Stimulating market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Human Granulocyte Colony-Stimulating market opportunities vary by end market size?
How does Recombinant Human Granulocyte Colony-Stimulating break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Recombinant Human Granulocyte Colony-Stimulating by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Recombinant Human Granulocyte Colony-Stimulating by Country/Region, 2019, 2023 & 2030
2.2 Recombinant Human Granulocyte Colony-Stimulating Segment by Type
2.2.1 Lenograstim (Granocyte)
2.2.2 Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
2.2.3 Others
2.3 Recombinant Human Granulocyte Colony-Stimulating Sales by Type
2.3.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2019-2024)
2.3.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue and Market Share by Type (2019-2024)
2.3.3 Global Recombinant Human Granulocyte Colony-Stimulating Sale Price by Type (2019-2024)
2.4 Recombinant Human Granulocyte Colony-Stimulating Segment by Application
2.4.1 Chemotherapy Induced Neutropenia
2.4.2 Before Blood Donation
2.4.3 Stem Cell Transplants
2.4.4 Others
2.5 Recombinant Human Granulocyte Colony-Stimulating Sales by Application
2.5.1 Global Recombinant Human Granulocyte Colony-Stimulating Sale Market Share by Application (2019-2024)
2.5.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue and Market Share by Application (2019-2024)
2.5.3 Global Recombinant Human Granulocyte Colony-Stimulating Sale Price by Application (2019-2024)
3 GLOBAL RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING BY COMPANY
3.1 Global Recombinant Human Granulocyte Colony-Stimulating Breakdown Data by Company
3.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Annual Sales by Company (2019-2024)
3.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Company (2019-2024)
3.2 Global Recombinant Human Granulocyte Colony-Stimulating Annual Revenue by Company (2019-2024)
3.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Company (2019-2024)
3.2.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Company (2019-2024)
3.3 Global Recombinant Human Granulocyte Colony-Stimulating Sale Price by Company
3.4 Key Manufacturers Recombinant Human Granulocyte Colony-Stimulating Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Human Granulocyte Colony-Stimulating Product Location Distribution
3.4.2 Players Recombinant Human Granulocyte Colony-Stimulating Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING BY GEOGRAPHIC REGION
4.1 World Historic Recombinant Human Granulocyte Colony-Stimulating Market Size by Geographic Region (2019-2024)
4.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Recombinant Human Granulocyte Colony-Stimulating Market Size by Country/Region (2019-2024)
4.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Annual Sales by Country/Region (2019-2024)
4.2.2 Global Recombinant Human Granulocyte Colony-Stimulating Annual Revenue by Country/Region (2019-2024)
4.3 Americas Recombinant Human Granulocyte Colony-Stimulating Sales Growth
4.4 APAC Recombinant Human Granulocyte Colony-Stimulating Sales Growth
4.5 Europe Recombinant Human Granulocyte Colony-Stimulating Sales Growth
4.6 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales Growth
5 AMERICAS
5.1 Americas Recombinant Human Granulocyte Colony-Stimulating Sales by Country
5.1.1 Americas Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2019-2024)
5.1.2 Americas Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2019-2024)
5.2 Americas Recombinant Human Granulocyte Colony-Stimulating Sales by Type
5.3 Americas Recombinant Human Granulocyte Colony-Stimulating Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Human Granulocyte Colony-Stimulating Sales by Region
6.1.1 APAC Recombinant Human Granulocyte Colony-Stimulating Sales by Region (2019-2024)
6.1.2 APAC Recombinant Human Granulocyte Colony-Stimulating Revenue by Region (2019-2024)
6.2 APAC Recombinant Human Granulocyte Colony-Stimulating Sales by Type
6.3 APAC Recombinant Human Granulocyte Colony-Stimulating Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Recombinant Human Granulocyte Colony-Stimulating by Country
7.1.1 Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2019-2024)
7.1.2 Europe Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2019-2024)
7.2 Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Type
7.3 Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating by Country
8.1.1 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2019-2024)
8.1.2 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2019-2024)
8.2 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Type
8.3 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Human Granulocyte Colony-Stimulating
10.3 Manufacturing Process Analysis of Recombinant Human Granulocyte Colony-Stimulating
10.4 Industry Chain Structure of Recombinant Human Granulocyte Colony-Stimulating
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Human Granulocyte Colony-Stimulating Distributors
11.3 Recombinant Human Granulocyte Colony-Stimulating Customer
12 WORLD FORECAST REVIEW FOR RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING BY GEOGRAPHIC REGION
12.1 Global Recombinant Human Granulocyte Colony-Stimulating Market Size Forecast by Region
12.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Forecast by Region (2025-2030)
12.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Recombinant Human Granulocyte Colony-Stimulating Forecast by Type
12.7 Global Recombinant Human Granulocyte Colony-Stimulating Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.1.3 Amgen Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 Qilu Pharmaceutical
13.2.1 Qilu Pharmaceutical Company Information
13.2.2 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.2.3 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Qilu Pharmaceutical Main Business Overview
13.2.5 Qilu Pharmaceutical Latest Developments
13.3 Shijiazhuang Pharmaceutical
13.3.1 Shijiazhuang Pharmaceutical Company Information
13.3.2 Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.3.3 Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Shijiazhuang Pharmaceutical Main Business Overview
13.3.5 Shijiazhuang Pharmaceutical Latest Developments
13.4 Kyowa Hakko Kirin
13.4.1 Kyowa Hakko Kirin Company Information
13.4.2 Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.4.3 Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Kyowa Hakko Kirin Main Business Overview
13.4.5 Kyowa Hakko Kirin Latest Developments
13.5 Gensci
13.5.1 Gensci Company Information
13.5.2 Gensci Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.5.3 Gensci Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Gensci Main Business Overview
13.5.5 Gensci Latest Developments
13.6 Amoytop Biotech
13.6.1 Amoytop Biotech Company Information
13.6.2 Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.6.3 Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Amoytop Biotech Main Business Overview
13.6.5 Amoytop Biotech Latest Developments
13.7 Hangzhou Jiuyuan
13.7.1 Hangzhou Jiuyuan Company Information
13.7.2 Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.7.3 Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Hangzhou Jiuyuan Main Business Overview
13.7.5 Hangzhou Jiuyuan Latest Developments
13.8 Huaxin
13.8.1 Huaxin Company Information
13.8.2 Huaxin Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.8.3 Huaxin Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Huaxin Main Business Overview
13.8.5 Huaxin Latest Developments
13.9 Triprime
13.9.1 Triprime Company Information
13.9.2 Triprime Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.9.3 Triprime Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Triprime Main Business Overview
13.9.5 Triprime Latest Developments
13.10 Sinovac
13.10.1 Sinovac Company Information
13.10.2 Sinovac Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.10.3 Sinovac Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Sinovac Main Business Overview
13.10.5 Sinovac Latest Developments
13.11 Zhaoke
13.11.1 Zhaoke Company Information
13.11.2 Zhaoke Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.11.3 Zhaoke Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Zhaoke Main Business Overview
13.11.5 Zhaoke Latest Developments
13.12 Kawin
13.12.1 Kawin Company Information
13.12.2 Kawin Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.12.3 Kawin Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Kawin Main Business Overview
13.12.5 Kawin Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Recombinant Human Granulocyte Colony-Stimulating by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Recombinant Human Granulocyte Colony-Stimulating by Country/Region, 2019, 2023 & 2030
2.2 Recombinant Human Granulocyte Colony-Stimulating Segment by Type
2.2.1 Lenograstim (Granocyte)
2.2.2 Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
2.2.3 Others
2.3 Recombinant Human Granulocyte Colony-Stimulating Sales by Type
2.3.1 Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2019-2024)
2.3.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue and Market Share by Type (2019-2024)
2.3.3 Global Recombinant Human Granulocyte Colony-Stimulating Sale Price by Type (2019-2024)
2.4 Recombinant Human Granulocyte Colony-Stimulating Segment by Application
2.4.1 Chemotherapy Induced Neutropenia
2.4.2 Before Blood Donation
2.4.3 Stem Cell Transplants
2.4.4 Others
2.5 Recombinant Human Granulocyte Colony-Stimulating Sales by Application
2.5.1 Global Recombinant Human Granulocyte Colony-Stimulating Sale Market Share by Application (2019-2024)
2.5.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue and Market Share by Application (2019-2024)
2.5.3 Global Recombinant Human Granulocyte Colony-Stimulating Sale Price by Application (2019-2024)
3 GLOBAL RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING BY COMPANY
3.1 Global Recombinant Human Granulocyte Colony-Stimulating Breakdown Data by Company
3.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Annual Sales by Company (2019-2024)
3.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Company (2019-2024)
3.2 Global Recombinant Human Granulocyte Colony-Stimulating Annual Revenue by Company (2019-2024)
3.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Company (2019-2024)
3.2.2 Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Company (2019-2024)
3.3 Global Recombinant Human Granulocyte Colony-Stimulating Sale Price by Company
3.4 Key Manufacturers Recombinant Human Granulocyte Colony-Stimulating Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Human Granulocyte Colony-Stimulating Product Location Distribution
3.4.2 Players Recombinant Human Granulocyte Colony-Stimulating Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING BY GEOGRAPHIC REGION
4.1 World Historic Recombinant Human Granulocyte Colony-Stimulating Market Size by Geographic Region (2019-2024)
4.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Recombinant Human Granulocyte Colony-Stimulating Market Size by Country/Region (2019-2024)
4.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Annual Sales by Country/Region (2019-2024)
4.2.2 Global Recombinant Human Granulocyte Colony-Stimulating Annual Revenue by Country/Region (2019-2024)
4.3 Americas Recombinant Human Granulocyte Colony-Stimulating Sales Growth
4.4 APAC Recombinant Human Granulocyte Colony-Stimulating Sales Growth
4.5 Europe Recombinant Human Granulocyte Colony-Stimulating Sales Growth
4.6 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales Growth
5 AMERICAS
5.1 Americas Recombinant Human Granulocyte Colony-Stimulating Sales by Country
5.1.1 Americas Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2019-2024)
5.1.2 Americas Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2019-2024)
5.2 Americas Recombinant Human Granulocyte Colony-Stimulating Sales by Type
5.3 Americas Recombinant Human Granulocyte Colony-Stimulating Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Human Granulocyte Colony-Stimulating Sales by Region
6.1.1 APAC Recombinant Human Granulocyte Colony-Stimulating Sales by Region (2019-2024)
6.1.2 APAC Recombinant Human Granulocyte Colony-Stimulating Revenue by Region (2019-2024)
6.2 APAC Recombinant Human Granulocyte Colony-Stimulating Sales by Type
6.3 APAC Recombinant Human Granulocyte Colony-Stimulating Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Recombinant Human Granulocyte Colony-Stimulating by Country
7.1.1 Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2019-2024)
7.1.2 Europe Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2019-2024)
7.2 Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Type
7.3 Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating by Country
8.1.1 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2019-2024)
8.1.2 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2019-2024)
8.2 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Type
8.3 Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Human Granulocyte Colony-Stimulating
10.3 Manufacturing Process Analysis of Recombinant Human Granulocyte Colony-Stimulating
10.4 Industry Chain Structure of Recombinant Human Granulocyte Colony-Stimulating
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Human Granulocyte Colony-Stimulating Distributors
11.3 Recombinant Human Granulocyte Colony-Stimulating Customer
12 WORLD FORECAST REVIEW FOR RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING BY GEOGRAPHIC REGION
12.1 Global Recombinant Human Granulocyte Colony-Stimulating Market Size Forecast by Region
12.1.1 Global Recombinant Human Granulocyte Colony-Stimulating Forecast by Region (2025-2030)
12.1.2 Global Recombinant Human Granulocyte Colony-Stimulating Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Recombinant Human Granulocyte Colony-Stimulating Forecast by Type
12.7 Global Recombinant Human Granulocyte Colony-Stimulating Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Amgen
13.1.1 Amgen Company Information
13.1.2 Amgen Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.1.3 Amgen Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Amgen Main Business Overview
13.1.5 Amgen Latest Developments
13.2 Qilu Pharmaceutical
13.2.1 Qilu Pharmaceutical Company Information
13.2.2 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.2.3 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Qilu Pharmaceutical Main Business Overview
13.2.5 Qilu Pharmaceutical Latest Developments
13.3 Shijiazhuang Pharmaceutical
13.3.1 Shijiazhuang Pharmaceutical Company Information
13.3.2 Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.3.3 Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Shijiazhuang Pharmaceutical Main Business Overview
13.3.5 Shijiazhuang Pharmaceutical Latest Developments
13.4 Kyowa Hakko Kirin
13.4.1 Kyowa Hakko Kirin Company Information
13.4.2 Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.4.3 Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Kyowa Hakko Kirin Main Business Overview
13.4.5 Kyowa Hakko Kirin Latest Developments
13.5 Gensci
13.5.1 Gensci Company Information
13.5.2 Gensci Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.5.3 Gensci Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Gensci Main Business Overview
13.5.5 Gensci Latest Developments
13.6 Amoytop Biotech
13.6.1 Amoytop Biotech Company Information
13.6.2 Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.6.3 Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Amoytop Biotech Main Business Overview
13.6.5 Amoytop Biotech Latest Developments
13.7 Hangzhou Jiuyuan
13.7.1 Hangzhou Jiuyuan Company Information
13.7.2 Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.7.3 Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Hangzhou Jiuyuan Main Business Overview
13.7.5 Hangzhou Jiuyuan Latest Developments
13.8 Huaxin
13.8.1 Huaxin Company Information
13.8.2 Huaxin Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.8.3 Huaxin Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Huaxin Main Business Overview
13.8.5 Huaxin Latest Developments
13.9 Triprime
13.9.1 Triprime Company Information
13.9.2 Triprime Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.9.3 Triprime Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Triprime Main Business Overview
13.9.5 Triprime Latest Developments
13.10 Sinovac
13.10.1 Sinovac Company Information
13.10.2 Sinovac Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.10.3 Sinovac Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Sinovac Main Business Overview
13.10.5 Sinovac Latest Developments
13.11 Zhaoke
13.11.1 Zhaoke Company Information
13.11.2 Zhaoke Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.11.3 Zhaoke Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Zhaoke Main Business Overview
13.11.5 Zhaoke Latest Developments
13.12 Kawin
13.12.1 Kawin Company Information
13.12.2 Kawin Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
13.12.3 Kawin Recombinant Human Granulocyte Colony-Stimulating Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Kawin Main Business Overview
13.12.5 Kawin Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Recombinant Human Granulocyte Colony-Stimulating Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Recombinant Human Granulocyte Colony-Stimulating Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Lenograstim (Granocyte)
Table 4. Major Players of Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
Table 5. Major Players of Others
Table 6. Global Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2019-2024) & (KG)
Table 7. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2019-2024)
Table 8. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Type (2019-2024) & ($ million)
Table 9. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Type (2019-2024)
Table 10. Global Recombinant Human Granulocyte Colony-Stimulating Sale Price by Type (2019-2024) & (USD/g)
Table 11. Global Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2019-2024) & (KG)
Table 12. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2019-2024)
Table 13. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Application (2019-2024)
Table 14. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Application (2019-2024)
Table 15. Global Recombinant Human Granulocyte Colony-Stimulating Sale Price by Application (2019-2024) & (USD/g)
Table 16. Global Recombinant Human Granulocyte Colony-Stimulating Sales by Company (2019-2024) & (KG)
Table 17. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Company (2019-2024)
Table 18. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Company (2019-2024) ($ Millions)
Table 19. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Company (2019-2024)
Table 20. Global Recombinant Human Granulocyte Colony-Stimulating Sale Price by Company (2019-2024) & (USD/g)
Table 21. Key Manufacturers Recombinant Human Granulocyte Colony-Stimulating Producing Area Distribution and Sales Area
Table 22. Players Recombinant Human Granulocyte Colony-Stimulating Products Offered
Table 23. Recombinant Human Granulocyte Colony-Stimulating Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Recombinant Human Granulocyte Colony-Stimulating Sales by Geographic Region (2019-2024) & (KG)
Table 27. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share Geographic Region (2019-2024)
Table 28. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Geographic Region (2019-2024) & ($ millions)
Table 29. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Geographic Region (2019-2024)
Table 30. Global Recombinant Human Granulocyte Colony-Stimulating Sales by Country/Region (2019-2024) & (KG)
Table 31. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country/Region (2019-2024)
Table 32. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Country/Region (2019-2024) & ($ millions)
Table 33. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country/Region (2019-2024)
Table 34. Americas Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2019-2024) & (KG)
Table 35. Americas Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country (2019-2024)
Table 36. Americas Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2019-2024) & ($ Millions)
Table 37. Americas Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country (2019-2024)
Table 38. Americas Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2019-2024) & (KG)
Table 39. Americas Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2019-2024) & (KG)
Table 40. APAC Recombinant Human Granulocyte Colony-Stimulating Sales by Region (2019-2024) & (KG)
Table 41. APAC Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Region (2019-2024)
Table 42. APAC Recombinant Human Granulocyte Colony-Stimulating Revenue by Region (2019-2024) & ($ Millions)
Table 43. APAC Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Region (2019-2024)
Table 44. APAC Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2019-2024) & (KG)
Table 45. APAC Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2019-2024) & (KG)
Table 46. Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2019-2024) & (KG)
Table 47. Europe Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country (2019-2024)
Table 48. Europe Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2019-2024) & ($ Millions)
Table 49. Europe Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country (2019-2024)
Table 50. Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2019-2024) & (KG)
Table 51. Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2019-2024) & (KG)
Table 52. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2019-2024) & (KG)
Table 53. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country (2019-2024)
Table 54. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2019-2024) & ($ Millions)
Table 55. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country (2019-2024)
Table 56. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2019-2024) & (KG)
Table 57. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2019-2024) & (KG)
Table 58. Key Market Drivers & Growth Opportunities of Recombinant Human Granulocyte Colony-Stimulating
Table 59. Key Market Challenges & Risks of Recombinant Human Granulocyte Colony-Stimulating
Table 60. Key Industry Trends of Recombinant Human Granulocyte Colony-Stimulating
Table 61. Recombinant Human Granulocyte Colony-Stimulating Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Recombinant Human Granulocyte Colony-Stimulating Distributors List
Table 64. Recombinant Human Granulocyte Colony-Stimulating Customer List
Table 65. Global Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Region (2025-2030) & (KG)
Table 66. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Region (2025-2030) & ($ millions)
Table 67. Americas Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Country (2025-2030) & (KG)
Table 68. Americas Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Country (2025-2030) & ($ millions)
Table 69. APAC Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Region (2025-2030) & (KG)
Table 70. APAC Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Region (2025-2030) & ($ millions)
Table 71. Europe Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Country (2025-2030) & (KG)
Table 72. Europe Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Country (2025-2030) & ($ millions)
Table 73. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Country (2025-2030) & (KG)
Table 74. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Country (2025-2030) & ($ millions)
Table 75. Global Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Type (2025-2030) & (KG)
Table 76. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 77. Global Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Application (2025-2030) & (KG)
Table 78. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 79. Amgen Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 80. Amgen Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 81. Amgen Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 82. Amgen Main Business
Table 83. Amgen Latest Developments
Table 84. Qilu Pharmaceutical Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 85. Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 86. Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 87. Qilu Pharmaceutical Main Business
Table 88. Qilu Pharmaceutical Latest Developments
Table 89. Shijiazhuang Pharmaceutical Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 90. Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 91. Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 92. Shijiazhuang Pharmaceutical Main Business
Table 93. Shijiazhuang Pharmaceutical Latest Developments
Table 94. Kyowa Hakko Kirin Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 95. Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 96. Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 97. Kyowa Hakko Kirin Main Business
Table 98. Kyowa Hakko Kirin Latest Developments
Table 99. Gensci Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 100. Gensci Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 101. Gensci Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 102. Gensci Main Business
Table 103. Gensci Latest Developments
Table 104. Amoytop Biotech Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 105. Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 106. Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 107. Amoytop Biotech Main Business
Table 108. Amoytop Biotech Latest Developments
Table 109. Hangzhou Jiuyuan Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 110. Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 111. Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 112. Hangzhou Jiuyuan Main Business
Table 113. Hangzhou Jiuyuan Latest Developments
Table 114. Huaxin Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 115. Huaxin Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 116. Huaxin Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 117. Huaxin Main Business
Table 118. Huaxin Latest Developments
Table 119. Triprime Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 120. Triprime Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 121. Triprime Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 122. Triprime Main Business
Table 123. Triprime Latest Developments
Table 124. Sinovac Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 125. Sinovac Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 126. Sinovac Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 127. Sinovac Main Business
Table 128. Sinovac Latest Developments
Table 129. Zhaoke Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 130. Zhaoke Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 131. Zhaoke Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 132. Zhaoke Main Business
Table 133. Zhaoke Latest Developments
Table 134. Kawin Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 135. Kawin Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 136. Kawin Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 137. Kawin Main Business
Table 138. Kawin Latest Developments
Table 1. Recombinant Human Granulocyte Colony-Stimulating Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Recombinant Human Granulocyte Colony-Stimulating Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Lenograstim (Granocyte)
Table 4. Major Players of Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
Table 5. Major Players of Others
Table 6. Global Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2019-2024) & (KG)
Table 7. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2019-2024)
Table 8. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Type (2019-2024) & ($ million)
Table 9. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Type (2019-2024)
Table 10. Global Recombinant Human Granulocyte Colony-Stimulating Sale Price by Type (2019-2024) & (USD/g)
Table 11. Global Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2019-2024) & (KG)
Table 12. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2019-2024)
Table 13. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Application (2019-2024)
Table 14. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Application (2019-2024)
Table 15. Global Recombinant Human Granulocyte Colony-Stimulating Sale Price by Application (2019-2024) & (USD/g)
Table 16. Global Recombinant Human Granulocyte Colony-Stimulating Sales by Company (2019-2024) & (KG)
Table 17. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Company (2019-2024)
Table 18. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Company (2019-2024) ($ Millions)
Table 19. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Company (2019-2024)
Table 20. Global Recombinant Human Granulocyte Colony-Stimulating Sale Price by Company (2019-2024) & (USD/g)
Table 21. Key Manufacturers Recombinant Human Granulocyte Colony-Stimulating Producing Area Distribution and Sales Area
Table 22. Players Recombinant Human Granulocyte Colony-Stimulating Products Offered
Table 23. Recombinant Human Granulocyte Colony-Stimulating Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Recombinant Human Granulocyte Colony-Stimulating Sales by Geographic Region (2019-2024) & (KG)
Table 27. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share Geographic Region (2019-2024)
Table 28. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Geographic Region (2019-2024) & ($ millions)
Table 29. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Geographic Region (2019-2024)
Table 30. Global Recombinant Human Granulocyte Colony-Stimulating Sales by Country/Region (2019-2024) & (KG)
Table 31. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country/Region (2019-2024)
Table 32. Global Recombinant Human Granulocyte Colony-Stimulating Revenue by Country/Region (2019-2024) & ($ millions)
Table 33. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country/Region (2019-2024)
Table 34. Americas Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2019-2024) & (KG)
Table 35. Americas Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country (2019-2024)
Table 36. Americas Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2019-2024) & ($ Millions)
Table 37. Americas Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country (2019-2024)
Table 38. Americas Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2019-2024) & (KG)
Table 39. Americas Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2019-2024) & (KG)
Table 40. APAC Recombinant Human Granulocyte Colony-Stimulating Sales by Region (2019-2024) & (KG)
Table 41. APAC Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Region (2019-2024)
Table 42. APAC Recombinant Human Granulocyte Colony-Stimulating Revenue by Region (2019-2024) & ($ Millions)
Table 43. APAC Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Region (2019-2024)
Table 44. APAC Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2019-2024) & (KG)
Table 45. APAC Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2019-2024) & (KG)
Table 46. Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2019-2024) & (KG)
Table 47. Europe Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country (2019-2024)
Table 48. Europe Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2019-2024) & ($ Millions)
Table 49. Europe Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country (2019-2024)
Table 50. Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2019-2024) & (KG)
Table 51. Europe Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2019-2024) & (KG)
Table 52. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Country (2019-2024) & (KG)
Table 53. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country (2019-2024)
Table 54. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Revenue by Country (2019-2024) & ($ Millions)
Table 55. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country (2019-2024)
Table 56. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Type (2019-2024) & (KG)
Table 57. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales by Application (2019-2024) & (KG)
Table 58. Key Market Drivers & Growth Opportunities of Recombinant Human Granulocyte Colony-Stimulating
Table 59. Key Market Challenges & Risks of Recombinant Human Granulocyte Colony-Stimulating
Table 60. Key Industry Trends of Recombinant Human Granulocyte Colony-Stimulating
Table 61. Recombinant Human Granulocyte Colony-Stimulating Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Recombinant Human Granulocyte Colony-Stimulating Distributors List
Table 64. Recombinant Human Granulocyte Colony-Stimulating Customer List
Table 65. Global Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Region (2025-2030) & (KG)
Table 66. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Region (2025-2030) & ($ millions)
Table 67. Americas Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Country (2025-2030) & (KG)
Table 68. Americas Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Country (2025-2030) & ($ millions)
Table 69. APAC Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Region (2025-2030) & (KG)
Table 70. APAC Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Region (2025-2030) & ($ millions)
Table 71. Europe Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Country (2025-2030) & (KG)
Table 72. Europe Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Country (2025-2030) & ($ millions)
Table 73. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Country (2025-2030) & (KG)
Table 74. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Country (2025-2030) & ($ millions)
Table 75. Global Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Type (2025-2030) & (KG)
Table 76. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 77. Global Recombinant Human Granulocyte Colony-Stimulating Sales Forecast by Application (2025-2030) & (KG)
Table 78. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 79. Amgen Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 80. Amgen Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 81. Amgen Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 82. Amgen Main Business
Table 83. Amgen Latest Developments
Table 84. Qilu Pharmaceutical Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 85. Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 86. Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 87. Qilu Pharmaceutical Main Business
Table 88. Qilu Pharmaceutical Latest Developments
Table 89. Shijiazhuang Pharmaceutical Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 90. Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 91. Shijiazhuang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 92. Shijiazhuang Pharmaceutical Main Business
Table 93. Shijiazhuang Pharmaceutical Latest Developments
Table 94. Kyowa Hakko Kirin Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 95. Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 96. Kyowa Hakko Kirin Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 97. Kyowa Hakko Kirin Main Business
Table 98. Kyowa Hakko Kirin Latest Developments
Table 99. Gensci Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 100. Gensci Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 101. Gensci Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 102. Gensci Main Business
Table 103. Gensci Latest Developments
Table 104. Amoytop Biotech Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 105. Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 106. Amoytop Biotech Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 107. Amoytop Biotech Main Business
Table 108. Amoytop Biotech Latest Developments
Table 109. Hangzhou Jiuyuan Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 110. Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 111. Hangzhou Jiuyuan Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 112. Hangzhou Jiuyuan Main Business
Table 113. Hangzhou Jiuyuan Latest Developments
Table 114. Huaxin Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 115. Huaxin Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 116. Huaxin Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 117. Huaxin Main Business
Table 118. Huaxin Latest Developments
Table 119. Triprime Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 120. Triprime Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 121. Triprime Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 122. Triprime Main Business
Table 123. Triprime Latest Developments
Table 124. Sinovac Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 125. Sinovac Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 126. Sinovac Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 127. Sinovac Main Business
Table 128. Sinovac Latest Developments
Table 129. Zhaoke Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 130. Zhaoke Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 131. Zhaoke Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 132. Zhaoke Main Business
Table 133. Zhaoke Latest Developments
Table 134. Kawin Basic Information, Recombinant Human Granulocyte Colony-Stimulating Manufacturing Base, Sales Area and Its Competitors
Table 135. Kawin Recombinant Human Granulocyte Colony-Stimulating Product Portfolios and Specifications
Table 136. Kawin Recombinant Human Granulocyte Colony-Stimulating Sales (KG), Revenue ($ Million), Price (USD/g) and Gross Margin (2019-2024)
Table 137. Kawin Main Business
Table 138. Kawin Latest Developments
LIST OF FIGURES
Figure 1. Picture of Recombinant Human Granulocyte Colony-Stimulating
Figure 2. Recombinant Human Granulocyte Colony-Stimulating Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Recombinant Human Granulocyte Colony-Stimulating Sales Growth Rate 2019-2030 (KG)
Figure 7. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Recombinant Human Granulocyte Colony-Stimulating Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Lenograstim (Granocyte)
Figure 10. Product Picture of Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
Figure 11. Product Picture of Others
Figure 12. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type in 2023
Figure 13. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Type (2019-2024)
Figure 14. Recombinant Human Granulocyte Colony-Stimulating Consumed in Chemotherapy Induced Neutropenia
Figure 15. Global Recombinant Human Granulocyte Colony-Stimulating Market: Chemotherapy Induced Neutropenia (2019-2024) & (KG)
Figure 16. Recombinant Human Granulocyte Colony-Stimulating Consumed in Before Blood Donation
Figure 17. Global Recombinant Human Granulocyte Colony-Stimulating Market: Before Blood Donation (2019-2024) & (KG)
Figure 18. Recombinant Human Granulocyte Colony-Stimulating Consumed in Stem Cell Transplants
Figure 19. Global Recombinant Human Granulocyte Colony-Stimulating Market: Stem Cell Transplants (2019-2024) & (KG)
Figure 20. Recombinant Human Granulocyte Colony-Stimulating Consumed in Others
Figure 21. Global Recombinant Human Granulocyte Colony-Stimulating Market: Others (2019-2024) & (KG)
Figure 22. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2023)
Figure 23. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Application in 2023
Figure 24. Recombinant Human Granulocyte Colony-Stimulating Sales Market by Company in 2023 (KG)
Figure 25. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Company in 2023
Figure 26. Recombinant Human Granulocyte Colony-Stimulating Revenue Market by Company in 2023 ($ Million)
Figure 27. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Company in 2023
Figure 28. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Geographic Region (2019-2024)
Figure 29. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Geographic Region in 2023
Figure 30. Americas Recombinant Human Granulocyte Colony-Stimulating Sales 2019-2024 (KG)
Figure 31. Americas Recombinant Human Granulocyte Colony-Stimulating Revenue 2019-2024 ($ Millions)
Figure 32. APAC Recombinant Human Granulocyte Colony-Stimulating Sales 2019-2024 (KG)
Figure 33. APAC Recombinant Human Granulocyte Colony-Stimulating Revenue 2019-2024 ($ Millions)
Figure 34. Europe Recombinant Human Granulocyte Colony-Stimulating Sales 2019-2024 (KG)
Figure 35. Europe Recombinant Human Granulocyte Colony-Stimulating Revenue 2019-2024 ($ Millions)
Figure 36. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales 2019-2024 (KG)
Figure 37. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Revenue 2019-2024 ($ Millions)
Figure 38. Americas Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country in 2023
Figure 39. Americas Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country in 2023
Figure 40. Americas Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2019-2024)
Figure 41. Americas Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2019-2024)
Figure 42. United States Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 43. Canada Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 44. Mexico Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 45. Brazil Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 46. APAC Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Region in 2023
Figure 47. APAC Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Regions in 2023
Figure 48. APAC Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2019-2024)
Figure 49. APAC Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2019-2024)
Figure 50. China Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 51. Japan Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 52. South Korea Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 53. Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 54. India Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 55. Australia Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 56. China Taiwan Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 57. Europe Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country in 2023
Figure 58. Europe Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country in 2023
Figure 59. Europe Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2019-2024)
Figure 60. Europe Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2019-2024)
Figure 61. Germany Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 62. France Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 63. UK Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 64. Italy Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 65. Russia Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 66. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country in 2023
Figure 67. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country in 2023
Figure 68. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2019-2024)
Figure 69. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2019-2024)
Figure 70. Egypt Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 71. South Africa Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 72. Israel Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 73. Turkey Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 74. GCC Country Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 75. Manufacturing Cost Structure Analysis of Recombinant Human Granulocyte Colony-Stimulating in 2023
Figure 76. Manufacturing Process Analysis of Recombinant Human Granulocyte Colony-Stimulating
Figure 77. Industry Chain Structure of Recombinant Human Granulocyte Colony-Stimulating
Figure 78. Channels of Distribution
Figure 79. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Forecast by Region (2025-2030)
Figure 80. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share Forecast by Region (2025-2030)
Figure 81. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share Forecast by Type (2025-2030)
Figure 82. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share Forecast by Type (2025-2030)
Figure 83. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share Forecast by Application (2025-2030)
Figure 84. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Recombinant Human Granulocyte Colony-Stimulating
Figure 2. Recombinant Human Granulocyte Colony-Stimulating Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Recombinant Human Granulocyte Colony-Stimulating Sales Growth Rate 2019-2030 (KG)
Figure 7. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Recombinant Human Granulocyte Colony-Stimulating Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Lenograstim (Granocyte)
Figure 10. Product Picture of Filgrastim (Neupogen, Zarzio, Nivestim, Ratiograstim)
Figure 11. Product Picture of Others
Figure 12. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type in 2023
Figure 13. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Type (2019-2024)
Figure 14. Recombinant Human Granulocyte Colony-Stimulating Consumed in Chemotherapy Induced Neutropenia
Figure 15. Global Recombinant Human Granulocyte Colony-Stimulating Market: Chemotherapy Induced Neutropenia (2019-2024) & (KG)
Figure 16. Recombinant Human Granulocyte Colony-Stimulating Consumed in Before Blood Donation
Figure 17. Global Recombinant Human Granulocyte Colony-Stimulating Market: Before Blood Donation (2019-2024) & (KG)
Figure 18. Recombinant Human Granulocyte Colony-Stimulating Consumed in Stem Cell Transplants
Figure 19. Global Recombinant Human Granulocyte Colony-Stimulating Market: Stem Cell Transplants (2019-2024) & (KG)
Figure 20. Recombinant Human Granulocyte Colony-Stimulating Consumed in Others
Figure 21. Global Recombinant Human Granulocyte Colony-Stimulating Market: Others (2019-2024) & (KG)
Figure 22. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2023)
Figure 23. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Application in 2023
Figure 24. Recombinant Human Granulocyte Colony-Stimulating Sales Market by Company in 2023 (KG)
Figure 25. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Company in 2023
Figure 26. Recombinant Human Granulocyte Colony-Stimulating Revenue Market by Company in 2023 ($ Million)
Figure 27. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Company in 2023
Figure 28. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Geographic Region (2019-2024)
Figure 29. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Geographic Region in 2023
Figure 30. Americas Recombinant Human Granulocyte Colony-Stimulating Sales 2019-2024 (KG)
Figure 31. Americas Recombinant Human Granulocyte Colony-Stimulating Revenue 2019-2024 ($ Millions)
Figure 32. APAC Recombinant Human Granulocyte Colony-Stimulating Sales 2019-2024 (KG)
Figure 33. APAC Recombinant Human Granulocyte Colony-Stimulating Revenue 2019-2024 ($ Millions)
Figure 34. Europe Recombinant Human Granulocyte Colony-Stimulating Sales 2019-2024 (KG)
Figure 35. Europe Recombinant Human Granulocyte Colony-Stimulating Revenue 2019-2024 ($ Millions)
Figure 36. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales 2019-2024 (KG)
Figure 37. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Revenue 2019-2024 ($ Millions)
Figure 38. Americas Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country in 2023
Figure 39. Americas Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country in 2023
Figure 40. Americas Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2019-2024)
Figure 41. Americas Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2019-2024)
Figure 42. United States Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 43. Canada Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 44. Mexico Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 45. Brazil Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 46. APAC Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Region in 2023
Figure 47. APAC Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Regions in 2023
Figure 48. APAC Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2019-2024)
Figure 49. APAC Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2019-2024)
Figure 50. China Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 51. Japan Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 52. South Korea Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 53. Southeast Asia Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 54. India Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 55. Australia Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 56. China Taiwan Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 57. Europe Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country in 2023
Figure 58. Europe Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country in 2023
Figure 59. Europe Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2019-2024)
Figure 60. Europe Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2019-2024)
Figure 61. Germany Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 62. France Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 63. UK Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 64. Italy Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 65. Russia Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 66. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Country in 2023
Figure 67. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share by Country in 2023
Figure 68. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Type (2019-2024)
Figure 69. Middle East & Africa Recombinant Human Granulocyte Colony-Stimulating Sales Market Share by Application (2019-2024)
Figure 70. Egypt Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 71. South Africa Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 72. Israel Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 73. Turkey Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 74. GCC Country Recombinant Human Granulocyte Colony-Stimulating Revenue Growth 2019-2024 ($ Millions)
Figure 75. Manufacturing Cost Structure Analysis of Recombinant Human Granulocyte Colony-Stimulating in 2023
Figure 76. Manufacturing Process Analysis of Recombinant Human Granulocyte Colony-Stimulating
Figure 77. Industry Chain Structure of Recombinant Human Granulocyte Colony-Stimulating
Figure 78. Channels of Distribution
Figure 79. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Forecast by Region (2025-2030)
Figure 80. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share Forecast by Region (2025-2030)
Figure 81. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share Forecast by Type (2025-2030)
Figure 82. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share Forecast by Type (2025-2030)
Figure 83. Global Recombinant Human Granulocyte Colony-Stimulating Sales Market Share Forecast by Application (2025-2030)
Figure 84. Global Recombinant Human Granulocyte Colony-Stimulating Revenue Market Share Forecast by Application (2025-2030)
More Publications
Global Late Stage Chronic Kidney Disease Drugs Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
September 2025
115 pages
Global Pharmaceutical Lactose Market Growth 2025-2031
US$ 3,660.00
December 2025
94 pages
Global Rheumatic Disorders Drug Market Growth (Status and Outlook) 2025-2031
US$ 3,660.00
December 2025
99 pages
